Project Details
Description
A Randomized Trial of the Combination of Ridaforolimus and Exemestane, compared to Ridaforolimus, Dalotuzumab and Exemestane in High proliferation, Estrogen recpptor positive Breast Cancer Patients
| Status | Finished |
|---|---|
| Effective start/end date | 4/23/12 → 4/30/17 |
Funding
- MERCK
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.